Biohaven Ltd. (NYSE:BHVN) Shares Sold by Eventide Asset Management LLC

Eventide Asset Management LLC lowered its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 37.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 399,827 shares of the company's stock after selling 234,837 shares during the period. Eventide Asset Management LLC owned approximately 0.42% of Biohaven worth $19,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of BHVN. Farallon Capital Management LLC grew its holdings in shares of Biohaven by 181.4% in the second quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company's stock worth $78,028,000 after purchasing an additional 1,449,000 shares during the last quarter. Armistice Capital LLC grew its stake in Biohaven by 74.8% in the 2nd quarter. Armistice Capital LLC now owns 1,396,968 shares of the company's stock worth $48,489,000 after acquiring an additional 597,705 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Biohaven by 563.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company's stock worth $25,416,000 after acquiring an additional 431,954 shares during the period. American Century Companies Inc. raised its stake in shares of Biohaven by 166.8% during the second quarter. American Century Companies Inc. now owns 511,237 shares of the company's stock valued at $17,745,000 after acquiring an additional 319,634 shares in the last quarter. Finally, ARS Investment Partners LLC boosted its holdings in shares of Biohaven by 47.8% in the second quarter. ARS Investment Partners LLC now owns 940,512 shares of the company's stock valued at $32,645,000 after purchasing an additional 304,141 shares during the period. Hedge funds and other institutional investors own 88.78% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on BHVN shares. Robert W. Baird raised their price objective on Biohaven from $58.00 to $60.00 and gave the stock an "outperform" rating in a report on Monday, September 23rd. Sanford C. Bernstein lifted their price objective on Biohaven from $55.00 to $66.00 and gave the company an "outperform" rating in a report on Tuesday, September 24th. Royal Bank of Canada lowered their price objective on shares of Biohaven from $66.00 to $58.00 and set an "outperform" rating for the company in a research note on Monday, November 25th. Bank of America raised their target price on shares of Biohaven from $52.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. upped their price target on shares of Biohaven from $55.00 to $68.00 and gave the stock an "overweight" rating in a research report on Thursday, October 3rd. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Biohaven presently has an average rating of "Buy" and a consensus price target of $62.75.

Insider Activity

In other news, Director Gregory Bailey purchased 5,000 shares of the stock in a transaction on Tuesday, September 24th. The stock was bought at an average price of $44.19 per share, with a total value of $220,950.00. Following the transaction, the director now owns 1,620,071 shares in the company, valued at $71,590,937.49. The trade was a 0.31 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John W. Childs acquired 21,052 shares of the business's stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the acquisition, the director now directly owns 21,052 shares of the company's stock, valued at approximately $999,970. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 16.00% of the company's stock.

Biohaven Price Performance

NYSE BHVN traded down $0.37 on Friday, hitting $46.01. The stock had a trading volume of 528,990 shares, compared to its average volume of 1,128,351. Biohaven Ltd. has a 52-week low of $26.80 and a 52-week high of $62.21. The business's fifty day moving average price is $49.77 and its 200 day moving average price is $41.37. The stock has a market cap of $4.65 billion, a price-to-earnings ratio of -4.92 and a beta of 1.31.

Biohaven (NYSE:BHVN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.03). As a group, sell-side analysts anticipate that Biohaven Ltd. will post -8.85 EPS for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.